Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Letrozole tablets (Furui)

Adjuvant therapy for early postmenopausal breast cancer patients is positive for estrogen or progesterone receptors. Adjuvant therapy for 5 years of post menopausal early breast cancer patients who have received tamoxifen adjuvant therapy is positive for estrogen or progesterone receptors. These patients should be treated with natural menopause or artificial induced menopause. More role
App download minus 10 yuan
Common name:
Letrozole Tablets
Product No.:
A14202154490
Approval No.:
Gyzz h19991001 (inquired by the State Drug Administration)
Jianke price:
¥144.00
Product specification:
2.5mg * 10 tablets * 3 plates 2.5mg*30s 2.5mg*10s
Manufacturer:
Jiangsu Hengrui Pharmaceutical Co., Ltd
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
Related classification
People who browse this product also browse
    Your recent history
      Wechat sweep: Jianke
      Health care doctor
      • Product introduction
      • instructions
      • Qualification certificate
      • Relevant information
      Product name Letrozole tablets (Furui)
      Main raw materials The main component of this product is letrozole, and its chemical name is 1 - [bis (4-cyanophenyl) methyl] - 1,2,4-triazole. Molecular formula: c17h11n5. Molecular weight: 285.31.
      Main role Adjuvant therapy for early postmenopausal breast cancer patients is positive for estrogen or progesterone receptors. Adjuvant therapy for 5 years of post menopausal early breast cancer patients who have received tamoxifen adjuvant therapy is positive for estrogen or progesterone receptors. These patients should be treated with natural menopause or artificial induced menopause.
      Product specification 2.5mg*10s
      Usage and dosage The recommended dose of this product is 2.5mg once a day. (see instructions for details)
      manufacturing enterprise Jiangsu Hengrui Pharmaceutical Co., Ltd
      Jianke commitment
      • Genuine guarantee, formal invoice

        Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

      • Private packaging, privacy protection

        When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

      • Efficient logistics and safe arrival

        All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

      • Three warehouses to ensure inventory

        Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

      [drug name] Letrozole tablets (Furui)

      [common name] Letrozole Tablets

      [specification and model] 2.5mg*10s

      [manufacturer] Jiangsu Hengrui Pharmaceutical Co., Ltd

      [drug type] Western medicine

      [approval No.] Gyzz h19991001

      [validity period] 36 months

      [functional indications] Adjuvant therapy for early postmenopausal breast cancer patients is positive for estrogen or progesterone receptors. Adjuvant therapy for 5 years of post menopausal early breast cancer patients who have received tamoxifen adjuvant therapy is positive for estrogen or progesterone receptors. These patients should be treated with natural menopause or artificial induced menopause.

      [usage and dosage] The recommended dose of this product is 2.5mg once a day. (see instructions for details)

      [adverse reactions] Summary of safety characteristics: Letrozole showed good safety in all advanced breast cancer patients receiving first-line treatment and second-line treatment, as well as subsequent intensive adjuvant therapy after adjuvant treatment and standard treatment with tamoxifen. About 81% of patients receiving adjuvant treatment (this product and tamoxifen control group), 87-88% of patients in sequential treatment group, with a median treatment duration of 60 months, 80% of patients receiving follow-up intensive adjuvant treatment (this product and placebo control group, with a median treatment duration of 60 months) and one third of patients with advanced metastasis and neoadjuvant treatment treated with this product had adverse reactions. The adverse reactions observed in the clinical study were mild to moderate. And many adverse reactions are related to estrogen deprivation. The most common adverse reactions in clinical trials were hot flashes, joint pain, nausea and fatigue. Many adverse reactions are due to normal pharmacological effects caused by estrogen deficiency (such as hot flashes, hair loss and vaginal bleeding). The adverse reactions listed in Table 1 come from clinical studies and post marketing reports. (see instructions for details)

      [precautions] Athletes should use it with caution.

      [taboo] Patients allergic to active drugs and / or any excipients. Premenopausal endocrine status, pregnant and lactating women (see [medication for pregnant and lactating women] and [pharmacology and toxicology]).

      [listing Permit Holder] Jiangsu Hengrui Pharmaceutical Co., Ltd

      [packaging unit] box

      [main ingredients] The main component of this product is letrozole, and its chemical name is 1 - [bis (4-cyanophenyl) methyl] - 1,2,4-triazole. Molecular formula: c17h11n5. Molecular weight: 285.31.

      [character] This product is dark yellow circular film coated tablets

      [applicable population] unlimited

      [medication for pregnant and lactating women] Letrozole is forbidden to be used in pregnant women (see [contraindication]). (see instructions for details)

      [medication for children] Letrozole should not be used in children or adolescents.

      [medication for elderly patients] Elderly patients do not need to adjust the dose.

      [storage] Sealed storage.

      Praise degree

      zero%

        reminder

        Dear customer:

        In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

        Letrozole tablets (Furui)

        ¥144.00

        reminder

        To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

        Please enter the correct verification code!
        Loding...
        Can't see clearly. Change one

        Dear customer:

        Your callback failed this time. Please re-enter the verification code to try. Thank you!